Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1. 系统已在2025-04-02 16:58:31对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(24)02722-3
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673624027223
其他信息:
出版社: Elsevier BV
作者: Anwen Xiong; Lei Wang; Jianhua Chen; Lin Wu; Baogang Liu; Jun Yao; Hua Zhong; Jie Li; Ying Cheng; Yulan Sun; Hui Ge; Jifang Yao; Qin Shi; Ming Zhou; Bolin Chen; Zhengxiang Han; Jinliang Wang; Qing Bu; Yanqiu Zhao; Junqiang Chen; Ligong Nie; Gaofeng Li; Xingya Li; Xinmin Yu; Yinghua Ji; Daqiang Sun; Xiaohong Ai; Qian Chu; Yu Lin; Jiqing Hao; Dingzhi Huang; Chengzhi Zhou; Jinlu Shan; Hongzhong Yang; Xuewen Liu; Jing Wang; Yanhong Shang; Xiaodong Mei; Jie Yang; Dongmei Lu; Mingxiu Hu; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Caicun Zhou
